Key clinical point: Targeting increased glycemic time-in-range may improve clinical outcomes in patients with type 2 diabetes.
Major finding: A 10% rise in average time in glycemic range linked with a 6% cut in major adverse cardiac events and a 10% drop in severe hypoglycemic events.
Study details: Post hoc analysis of data from 5,774 patients from the DEVOTE trial.
Disclosures: DEVOTE was funded by Novo Nordisk. Dr. Bergenstal has had financial relationships with Novo Nordisk and several other companies.
Bergenstal R et al. EASD 2020, Abstract 159.